Hospira, Korea’s Celltrion Get EU Nod For First Monoclonal Antibody Biosimilar
Executive Summary
EMA recommends approval for two brands of Celltrion’s infliximab, one to be marketed by Hospira, as Europe moves closer to its first MAb biosimilar. The positive decision is significant not only because the product will take on J&J/Merck’s bestselling Remicade in an era of budgetary pressures, but also because of its breadth. It is for all indications already approved in Europe for Remicade.
You may also be interested in...
Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution
If approved in Europe this year, as expected, Celltrion/Hospira’s biosimilar infliximab will provide a compelling test of whether and how quickly budgetary pressures can override physician caution. It will also set the stage for the $70 billion worth of copycat antibodies in development.
Korea's Celltrion In Deal With U.S.-based Hospira For Biogeneric Sales; M&A Hinted At
SEOUL - South Korea's Celltrion inked an agreement with U.S.-based Hospira to collaborate on manufacturing and marketing Celltrion's eight biogeneric products in global markets including the U.S. and Europe
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.